1
|
Oppen K, Brede C, Skadberg Ø, Steinsvik T, Holter JC, Michelsen AE, Heggelund L. Hepcidin analysis in pneumonia: Comparison of immunoassay and LC-MS/MS. Ann Clin Biochem 2023; 60:298-305. [PMID: 36759502 PMCID: PMC10552342 DOI: 10.1177/00045632231159529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/07/2023] [Indexed: 02/11/2023]
Abstract
BACKGROUND The iron-regulatory hormone hepcidin is a promising biomarker to differentiate anaemia of inflammation from iron deficiency. Plasma hepcidin concentrations increase substantially during inflammation, and the amount of smaller, non-biologically active isoforms of hepcidin increase in inflammatory conditions. These smaller isoforms are measured in some, but not all analytical methods. Thus, we evaluated the comparability of two analytical methods with different isoform selectivity during and after acute-phase pneumonia as a highly inflammatory model disease. METHODS Blood samples from a cohort of 267 hospitalized community-acquired pneumonia patients collected at admission and a 6-week follow-up were analysed. Hepcidin was measured in plasma by an immunoassay, which recognizes all hepcidin isoforms, and a liquid chromatography tandem mass spectrometry (LC-MS/MS), which selectively measures the bioactive hepcidin-25. Additionally, a subset of serum samples was analysed by LC-MS/MS. RESULTS Hepcidin measurements by immunoassay were higher compared with LC-MS/MS. The relative mean difference of hepcidin plasma concentrations between the two analytical methods was larger in admission samples than in follow-up samples (admission samples <200 ng/mL: 37%, admission samples >200 ng/mL: 78%, follow-up samples >10 ng/mL: 22%). During acute-phase pneumonia, serum concentrations were on average 22% lower than plasma concentrations when measured by LC-MS/MS. CONCLUSIONS Immunoassay measured higher hepcidin concentrations compared with LC-MS/MS, with more pronounced differences in high-concentration samples during acute-phase pneumonia. These findings should be considered in local method validations and in future harmonization and standardization optimization of hepcidin measurements.
Collapse
Affiliation(s)
- Kjersti Oppen
- Department of Laboratory Medicine, Drammen Hospital, Vestre Viken Hospital Trust, Norway
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Norway
- Institute of Clinical Medicine, University of Oslo, Norway
| | - Cato Brede
- Department of Medical Biochemistry, Stavanger University Hospital, Norway
- Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Norway
| | - Øyvind Skadberg
- Department of Medical Biochemistry, Stavanger University Hospital, Norway
| | - Trude Steinsvik
- Department of Laboratory Medicine, Drammen Hospital, Vestre Viken Hospital Trust, Norway
| | - Jan Cato Holter
- Institute of Clinical Medicine, University of Oslo, Norway
- Department of Microbiology, Oslo University Hospital, Norway
| | - Annika E Michelsen
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Norway
- Institute of Clinical Medicine, University of Oslo, Norway
| | - Lars Heggelund
- Department of Internal Medicine, Drammen Hospital, Vestre Viken Hospital Trust, Norway
- Department of Clinical Science, Bergen Integrated Diagnostic Stewardship Cluster, Faculty of Medicine, University of Bergen, Norway
| |
Collapse
|
2
|
Gutschow P, Han H, Olbina G, Westerman K, Nemeth E, Ganz T, Copeland K, Westerman M, Ostland V. Clinical Immunoassay for Human Hepcidin Predicts Iron Deficiency in First-Time Blood Donors. J Appl Lab Med 2020; 5:943-953. [PMID: 32674118 PMCID: PMC7497288 DOI: 10.1093/jalm/jfaa038] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2019] [Accepted: 02/03/2020] [Indexed: 12/21/2022]
Abstract
BACKGROUND Serum markers currently used as indicators of iron status have clinical limitations. Hepcidin, a key regulator of iron homeostasis, is reduced in iron deficiency (ID) and increased in iron overload. We describe the first CLIA-validated immunoassay with excellent accuracy and precision to quantify human serum hepcidin. Its diagnostic utility for detecting ID in first-time blood donors was demonstrated. METHODS A monoclonal competitive ELISA (C-ELISA) was developed for the quantitation of human hepcidin and validated according to CLIA guidelines. Sera from nonanemic first-time blood donors (n = 292) were analyzed for hepcidin, ferritin, transferrin, and serum iron. Logistic regression served to determine the utility of hepcidin as a predictor of ID. RESULTS The C-ELISA was specific for human hepcidin and had a low limit of quantitation (4.0 ng/mL). The hepcidin concentration measured with the monoclonal C-ELISA was strongly correlated with a previously established, extensively tested polyclonal C-ELISA (Blood 2008;112:4292-7) (r = 0.95, P < 0.001). The area under the receiver operating characteristic curve for hepcidin as a predictor of ID, defined by 3 ferritin concentration thresholds, was >0.9. For predicting ID defined by ferritin <15 ng/mL, hepcidin <10 ng/mL yielded sensitivity of 93.1% and specificity of 85.5%, whereas the same hepcidin cutoff for ferritin <30 ng/mL yielded sensitivity of 67.6% and specificity of 91.7%. CONCLUSION The clinical measurement of serum hepcidin concentrations was shown to be a potentially useful tool for diagnosing ID.
Collapse
Affiliation(s)
| | | | | | | | - Elizabeta Nemeth
- Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
| | - Tomas Ganz
- Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
| | | | | | | |
Collapse
|
3
|
Abbati G, Incerti F, Boarini C, Pileri F, Bocchi D, Ventura P, Buzzetti E, Pietrangelo A. Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anemia. Intern Emerg Med 2019; 14:423-431. [PMID: 30499070 DOI: 10.1007/s11739-018-1993-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2018] [Accepted: 11/20/2018] [Indexed: 12/11/2022]
Abstract
Iron deficiency anemia (IDA) is one of the most common complications of inflammatory bowel disease (IBD). We planned a prospective study to address tolerability and efficacy of sucrosomial iron, a new oral formulation of ferric pyrophosphate, in IBD patients. Thirty patients with a confirmed diagnosis of Crohn's Disease (CD) or ulcerative colitis (UC) and mild IDA were enrolled. Patients with severe IBD were excluded. All patients underwent 12 weeks of oral treatment with 30 mg/day of sucrosomial iron. Treatment compliance and adverse events were investigated every 4 weeks. Iron status, hematological parameters and IBD activity scores were determined at baseline and at the end of treatment, as well as serum hepcidin and non-transferrin bound iron (NTBI) levels. Twenty-four (80%) patients took more than 90% of the prescribed regimen. Forty-four adverse events (AEs) were recorded, but none of them is considered certainly or probably related to the study treatment. Interestingly, only eleven gastrointestinal events were recorded in 9 (30%) patients. At the end of treatment, all iron parameters improved significantly and Hb increased in 86% of patients (from 11.67 to 12.37 g/dl, p = 0.001). Serum hepcidin showed a significant increase in 79% of patients and became positively correlated with C-reactive protein (CRP) at the end of the study, while NTBI remained below the detection threshold after iron supplementation. The IBD activity scores improved in both CD and UC. This pilot interventional study supports the therapeutic use of sucrosomial iron in IBD and paves the way for future studies in larger or more difficult IBD populations.
Collapse
Affiliation(s)
- Gianluca Abbati
- Division of Internal Medicine 2 and Center for Hemochromatosis, University of Modena and Reggio Emilia, Via DEL Pozzo 71, 41124, Modena, Italy.
| | - Federica Incerti
- Division of Internal Medicine 2 and Center for Hemochromatosis, University of Modena and Reggio Emilia, Via DEL Pozzo 71, 41124, Modena, Italy
| | - Chiara Boarini
- Division of Internal Medicine 2 and Center for Hemochromatosis, University of Modena and Reggio Emilia, Via DEL Pozzo 71, 41124, Modena, Italy
| | - Francesca Pileri
- Division of Internal Medicine 2 and Center for Hemochromatosis, University of Modena and Reggio Emilia, Via DEL Pozzo 71, 41124, Modena, Italy
| | - Davide Bocchi
- Division of Internal Medicine 2 and Center for Hemochromatosis, University of Modena and Reggio Emilia, Via DEL Pozzo 71, 41124, Modena, Italy
| | - Paolo Ventura
- Division of Internal Medicine 2 and Center for Hemochromatosis, University of Modena and Reggio Emilia, Via DEL Pozzo 71, 41124, Modena, Italy
| | - Elena Buzzetti
- Division of Internal Medicine 2 and Center for Hemochromatosis, University of Modena and Reggio Emilia, Via DEL Pozzo 71, 41124, Modena, Italy
| | - Antonello Pietrangelo
- Division of Internal Medicine 2 and Center for Hemochromatosis, University of Modena and Reggio Emilia, Via DEL Pozzo 71, 41124, Modena, Italy
| |
Collapse
|
4
|
Wittkamp C, Traeger L, Ellermann I, Eveslage M, Steinbicker AU. Hepcidin as a potential predictor for preoperative anemia treatment with intravenous iron-A retrospective pilot study. PLoS One 2018; 13:e0201153. [PMID: 30089125 PMCID: PMC6082514 DOI: 10.1371/journal.pone.0201153] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2018] [Accepted: 07/08/2018] [Indexed: 12/14/2022] Open
Abstract
Preoperative anemia occurs in about one third of patients who undergo elective surgery and is associated with an impaired outcome. Therefore, screening of preoperative anemia was established in the context of a multidisciplinary Patient Blood Management (PBM) program at the University Hospital of Muenster, Germany. Anemic patients without contraindications were treated with intravenous (IV) iron (ferric carboxymaltose) to increase their hemoglobin (Hgb) levels and hence to treat anemia prior to surgery. Interestingly, we detected a large variability in the response of Hgb levels after IV iron administration. Systemic iron homeostasis is mainly regulated by the hepatic hormone hepcidin, which regulates the cell surface expression of the sole known iron exporter ferroportin. The objective of this retrospective pilot study was to analyze the potential of hepcidin to predict the response of anemic patients to preoperative IV iron treatment measured as increase in Hgb. Serum samples of non-anemic (n = 48), untreated anemic (n = 64) and anemic patients treated with IV iron (n = 79), in total 191 patients, were collected between October 2014 until June 2016. Serum hepcidin levels were determined and data were analyzed retrospectively. The analysis revealed at first a correlation between serum hepcidin levels and the parameters of the iron status. Second, patients treated with IV iron showed a noticeably higher increase in their delta Hgb level between PBM consultation and surgery (0.45g/dl [0.05, 1.05] compared to patients without IV iron (0.1g/dl [-0.48, 0.73], *p = 0.03). Patients were then grouped into ‘non-responders’, defined as delta Hgb <0.6g/dl and ‘responders’, with delta Hgb ≥0.6g/dl between the day of IV iron treatment and the day of surgery. Within normal ranges and clinically unapparent, a statistically noticeable difference between responders and non-responders was found for CRP and leukocytes. Serum hepcidin levels were higher in the group of non-responders (10.6ng/ml [3.93, 34.77]) compared to responders (2.1ng/ml [0.25, 7.97], *p = 0.04). To conclude, the data of this retrospective pilot study indicate that hepcidin might be a promising biomarker to predict a patient`s responsiveness to IV iron in preoperative anemia treatment. Prospective studies have to investigate serum hepcidin levels as a biomarker to guide physician`s decision on IV iron substitution.
Collapse
Affiliation(s)
- Christina Wittkamp
- Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Muenster, University of Muenster, Muenster, Germany
| | - Lisa Traeger
- Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Muenster, University of Muenster, Muenster, Germany
| | - Ines Ellermann
- Department of Pharmacy, University Hospital Muenster, University of Muenster, Muenster, Germany
| | - Maria Eveslage
- Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany
| | - Andrea U. Steinbicker
- Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Muenster, University of Muenster, Muenster, Germany
- * E-mail:
| |
Collapse
|
5
|
Sarıkaya B, Dursun AD, Taylan Deveden EY, Pınar L. Interleukin-6 and hepcidin expression changes in cardiac tissue of long-term trained and untrained rats after exhaustive exercise. Turk J Med Sci 2017; 47:1940-1946. [PMID: 29306260 DOI: 10.3906/sag-1703-73] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Background/aim: Exercise benefits the cardiovascular system, but strenuous exercise can cause cardiac damage and induce cytokine production, particularly that of interleukin-6 (IL-6). Hepcidin, which is primarily regulated by IL-6, increases after exercise. Hepcidin is a possible protective factor against the adverse effects of strenuous exercise such as oxidative stress. The aim of the study is to reveal that training increases hepcidin and attenuates increased levels of IL-6 in the hearts of exhaustively exercised rats by comparing the IL-6 and hepcidin mRNA expression levels in trained and untrained groups.Materials and methods: Thirty male Wistar albino rats were assigned to the following groups: sedentary controls (Con); untrained animals that acutely completed exhaustive exercise and were sacrificed immediately after exhaustion (UT-i) or 1 day after exhaustion (UT-1); and long-term trained animals that completed exhaustive exercise and were sacrificed immediately after exhaustion (T-i) or 1 day after exhaustion (T-1). mRNA levels were examined by reverse transcription PCR. Results: IL-6 levels significantly increased in the UT-i, T-i, and T-1 groups compared to the Con group (P = 0.000, P = 0.024, P = 0.001), with maximal IL-6 expression found in the UT-i group. Hepcidin levels significantly increased in the T-1 group (P = 0.000) compared to the control. Conclusion: Increased IL-6 levels in rats show that exhaustive exercise can cause cardiac inflammation. However, long-term training attenuated the severity of the inflammation. The possible protective effect of increased hepcidin in the trained groups can be explained by the antiinflammatory effects of IL-6 and long-term training.
Collapse
|
6
|
Bros P, Josephs RD, Stoppacher N, Cazals G, Lehmann S, Hirtz C, Wielgosz RI, Delatour V. Impurity determination for hepcidin by liquid chromatography-high resolution and ion mobility mass spectrometry for the value assignment of candidate primary calibrators. Anal Bioanal Chem 2017; 409:2559-2567. [PMID: 28138741 DOI: 10.1007/s00216-017-0202-4] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2016] [Revised: 12/23/2016] [Accepted: 01/10/2017] [Indexed: 11/28/2022]
Abstract
In metrology institutes, the state-of-the-art for purity analysis of peptides/proteins mainly addresses short and unfolded peptides. Important developments are anticipated for the characterization of nonlinear peptides or proteins. Hepcidin 1-25 is an interesting model system because this small protein contains four disulfide bridges with a particular connectivity that is difficult to reproduce and could induce a bias in quantification. Hepcidin 1-25 is involved in iron-related disorders and anemia, in an inflammatory context, and its clinical relevance in neurodegenerative disorders is under investigation. It is also an emerging biomarker. Recent inter-laboratory studies showed a need for standardization of hepcidin assay and the need to produce certified reference materials. This paper discusses two hepcidin standards from different synthesis pathways that have been characterized by high-resolution mass spectrometry and ion mobility mass spectrometry.
Collapse
Affiliation(s)
- Pauline Bros
- Laboratoire National de Métrologie et d'Essais (LNE), 1 Rue Gaston Boissier, 75015, Paris, France
- Departement de Chimie, Bureau International des Poids et Mesures (BIPM), Pavillon de Breteuil, 92312, Sèvres, France
- Laboratoire de Biochimie et de Protéomique Clinique - Institut de Médecine Régénérative et Biothérapies (LBPC-IRMB), CHU de Montpellier, 80 rue Augustin Fliche, 34091, Montpellier, France
| | - Ralf D Josephs
- Departement de Chimie, Bureau International des Poids et Mesures (BIPM), Pavillon de Breteuil, 92312, Sèvres, France.
| | - Norbert Stoppacher
- Departement de Chimie, Bureau International des Poids et Mesures (BIPM), Pavillon de Breteuil, 92312, Sèvres, France
| | - Guillaume Cazals
- Laboratoire de Mesures Physiques, Place Eugène Bataillon, 34095, Montpellier, France
| | - Sylvain Lehmann
- Laboratoire de Biochimie et de Protéomique Clinique - Institut de Médecine Régénérative et Biothérapies (LBPC-IRMB), CHU de Montpellier, 80 rue Augustin Fliche, 34091, Montpellier, France
| | - Christophe Hirtz
- Laboratoire de Biochimie et de Protéomique Clinique - Institut de Médecine Régénérative et Biothérapies (LBPC-IRMB), CHU de Montpellier, 80 rue Augustin Fliche, 34091, Montpellier, France
| | - Robert I Wielgosz
- Departement de Chimie, Bureau International des Poids et Mesures (BIPM), Pavillon de Breteuil, 92312, Sèvres, France
| | - Vincent Delatour
- Laboratoire National de Métrologie et d'Essais (LNE), 1 Rue Gaston Boissier, 75015, Paris, France
| |
Collapse
|
7
|
Yalovenko TM, Todor IM, Lukianova NY, Chekhun VF. Hepcidin as a possible marker in determination of malignancy degree and sensitivity of breast cancer cells to cytostatic drugs. Exp Oncol 2016; 38:84-88. [PMID: 27356575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
AIM To investigate the role of hepcidin (Hepc) in the formation of cells malignant phenotype in vitro and its expression in the dyna-mics of growth of Walker-256 carcinosarcoma with different sensitivity to doxorubicin (Dox). MATERIALS AND METHODS The cell lines used in the analysis included T47D, MCF-7, MDA-MB-231, MDA-MB-468, MCF/CP, and MCF/Dox. Hepc expression was studied by immunocytochemical method. "Free" iron content was determined by EPR spectroscopy. Determination of Hepc expression in homogenates of tumor tissue and in blood serum of rats with Dox-sensitive and -resistant Walker-256 carcinosarcoma was performed. RESULTS It was found that Hepc levels in breast cancer (BC) cells with high degree of malignancy (MDA-MB-231, MDA-MB-468) and drug-resistant phenotype (MCF/CP, MCF/Dox) were by 1.5-2 times higher (p < 0.05) in comparison with sensitive and less malignant BC cells. The development of drug-resistant phenotype in Walker-256 carcinosarcoma cells was accompanied by increasing of Hepc and "free" iron content (by 2.4 and 1.2 times, respectively). CONCLUSION The data of in vitro and in vivo research evidenced on involvement of Hepc in formation of BC cells malignant phenotype and their resistance to Dox.
Collapse
Affiliation(s)
- T M Yalovenko
- R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv 03022, Ukraine
| | | | - N Y Lukianova
- R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv 03022, Ukraine
| | - V F Chekhun
- R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv 03022, Ukraine
| |
Collapse
|
8
|
Winner MW, Sharkey-Toppen T, Zhang X, Pennell ML, Simonetti OP, Zweier JL, Vaccaro PS, Raman SV. Iron and noncontrast magnetic resonance T2* as a marker of intraplaque iron in human atherosclerosis. J Vasc Surg 2015; 61:1556-64. [PMID: 24674272 PMCID: PMC4175307 DOI: 10.1016/j.jvs.2014.02.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2013] [Revised: 02/04/2014] [Accepted: 02/06/2014] [Indexed: 12/21/2022]
Abstract
OBJECTIVE Iron has been implicated in atherogenesis and plaque destabilization, whereas less is known about iron-related proteins in this disease. We compared ex vivo quantities with in vivo vessel wall T2*, which is a noncontrast magnetic resonance relaxation time that quantitatively shortens with increased tissue iron content. We also tested the hypothesis that patients with carotid atherosclerosis have abnormal T2* times vs controls that would help support a role for iron in human atherosclerosis. METHODS Forty-six patients undergoing carotid endarterectomy and 14 subjects without carotid disease were prospectively enrolled to undergo carotid magnetic resonance imaging. Ex vivo measurements were performed on explanted plaque and 17 mammary artery samples. RESULTS Plaques vs normal arteries had higher levels of ferritin (median, 7.3 [interquartile range (IQR), 4-13.8] vs 1.0 [IQR, 0.6-1.3] ng/mg; P < .001) and oxidized low-density lipoprotein (median, 0.17 [IQR, 0.12-0.30] vs 0.01 [IQR, 0.003-0.03] ng/mg; P < .001) as well as hepcidin (median, 8.7 [IQR, 4.6-12.4] vs 2.6 [IQR, 1.3-7.0] ng/mL; P = .03); serum hepcidin levels did not distinguish atherosclerosis patients from controls (median, 40.6 [IQR, 18.8-88.6] vs 33.9 [IQR, 17.6-55.2]; P = .42). Shorter in vivo T2* paralleled larger plaque volume (ρ = -.44; P = .01), and diseased arteries had shorter T2* values compared with controls (median, 17.7 ± 4.3 vs 23.0 ± 2.4 ms; P < .001). CONCLUSIONS Diseased arteries have greater levels of iron-related proteins ex vivo and shorter T2* times in vivo. Further studies should help define the role of T2* as a biomarker of iron and atherosclerosis.
Collapse
Affiliation(s)
- Marshall W Winner
- The Ohio State University, Davis Heart and Lung Research Institute, Columbus, Ohio
| | | | - Xiaolan Zhang
- The Ohio State University, Davis Heart and Lung Research Institute, Columbus, Ohio
| | - Michael L Pennell
- The Ohio State University, Davis Heart and Lung Research Institute, Columbus, Ohio
| | - Orlando P Simonetti
- The Ohio State University, Davis Heart and Lung Research Institute, Columbus, Ohio
| | - Jay L Zweier
- The Ohio State University, Davis Heart and Lung Research Institute, Columbus, Ohio
| | - Patrick S Vaccaro
- The Ohio State University, Davis Heart and Lung Research Institute, Columbus, Ohio
| | - Subha V Raman
- The Ohio State University, Davis Heart and Lung Research Institute, Columbus, Ohio.
| |
Collapse
|
9
|
Fan J, Niu S, Dong A, Shi J, Wu HJ, Fine DH, Tian Y, Zhou C, Liu X, Sun T, Anderson GJ, Ferrari M, Nie G, Hu Y, Zhao Y. Nanopore film based enrichment and quantification of low abundance hepcidin from human bodily fluids. Nanomedicine 2014; 10:879-88. [PMID: 24566273 PMCID: PMC4077980 DOI: 10.1016/j.nano.2014.02.005] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/18/2013] [Revised: 01/29/2014] [Accepted: 02/02/2014] [Indexed: 11/20/2022]
Abstract
Endogenous peptides that represent biological and pathological information of disease have attracted interest for diagnosis. However, the extraction of those low abundance peptides is still a challenge because of the complexity of human bodily fluids (HBF). Hepcidin, a peptide hormone, has been recognized as a biomarker for iron-related diseases. There is no rapid and reliable way to enrich them from HBF. Here we describe a peptide extraction approach based on nanoporous silica thin films to successfully detect hepcidin from HBF. Cooperative functions of nanopore to biomolecule, including capillary adsorption, size-exclusion and electrostatic interaction, were systematically investigated to immobilize the target peptide. To promote this new approach to clinical practices, we further applied it to successfully assay the hepcidin levels in HBF provided by healthy volunteers and patients suffering from inflammation. Our finding provides a high-throughput, rapid, label-free and cost-effective detection method for capturing and quantifying low abundance peptides from HBF. FROM THE CLINICAL EDITOR Diagnosing diseases with low concentration peptide biomarkers remains challenging. This team of authors describes a peptide extraction approach based on nanoporous silica thin films to successfully detect low concentrations of hepcidin from human body fluids collected from 119 healthy volunteers and 19 inflammation patients.
Collapse
Affiliation(s)
- Jia Fan
- Chinese Academy of Science Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China, Beijing, China; Department of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX, USA
| | - Shiwen Niu
- Chinese Academy of Science Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China, Beijing, China; College of Pharmaceutical Science, Jilin University, Changchun, China
| | - Ailian Dong
- Chinese Academy of Science Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China, Beijing, China; The First Affiliated Hospital of Jilin University, Changchun, China
| | - Jian Shi
- Chinese Academy of Science Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China, Beijing, China
| | - Hung-Jen Wu
- Department of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX, USA
| | - Daniel H Fine
- Department of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX, USA
| | - Yaping Tian
- Department of Clinical Biochemistry, Chinese PLA General Hospital, Beijing, China
| | - Chunxi Zhou
- Bruker Daltonics Inc. Beijing Office, Beijing, China
| | - Xuewu Liu
- Department of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX, USA
| | - Tong Sun
- Department of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX, USA
| | - Gregory J Anderson
- Queensland Institute of Medical Research, Royal Brisbane Hospital, Brisbane, Queensland, Australia
| | - Mauro Ferrari
- Department of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX, USA; Weill Cornell Medical College of Cornell University, New York City, NY, USA
| | - Guangjun Nie
- Chinese Academy of Science Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China, Beijing, China
| | - Ye Hu
- Department of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX, USA; Weill Cornell Medical College of Cornell University, New York City, NY, USA.
| | - Yuliang Zhao
- Chinese Academy of Science Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China, Beijing, China.
| |
Collapse
|